Supreme Extends Due Diligence and Cancels Private Placement
April 15 2014 - 9:51AM
Marketwired
Supreme Extends Due Diligence and Cancels Private Placement
CALGARY, ALBERTA--(Marketwired - Apr 15, 2014) - Supreme
Pharmaceuticals Inc. (the "Company") (OTCBB:SPRWF)(TSX-VENTURE:SL)
reports that the parties to the agreement to acquire the South
Okanagan producing medical marijuana facility, have mutually agreed
upon an extension of the due diligence period to April 29th,
2014.
In addition, the
Company has cancelled its plans for the previously announced
private placement.
SUPREME
PHARMACEUTICALS INC.
David Stadnyk,
President & CEO
Neither TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
FORWARD LOOKING
INFORMATION
This News Release
contains forward-looking statements. The use of any of the words
"anticipate", "continue", "estimate", "expect", "may", "will",
"project", "should", "believe" and similar expressions are intended
to identify forward-looking statements. Although the Company
believes that the expectations and assumptions on which the
forward-looking statements are based are reasonable, undue reliance
should not be placed on the forward-looking statements because the
Company can give no assurance that they will prove to be correct.
Since forward-looking statements address future events and
conditions, by their very nature they involve inherent risks and
uncertainties. These statements speak only as of the date of this
News Release. Actual results could differ materially from those
currently anticipated due to a number of factors and risks
including various risk factors discussed in the Company's
disclosure documents which can be found under the Company's profile
on www.sedar.com. This News Release contains "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E the Securities Exchange Act of
1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.
Supreme Pharmaceuticals Inc.David StadnykPresident &
CEO(647)
340-6744info@supremepharmaceuticals.comwww.supremepharmaceuticals.com